CO5_2020

and China to accommodate the requested materials with little to no impact to existing customers. What kind of innovation, technologies are you focusing your activity on to secure the supply chain and its quality? Flamma has invested in many technologies including containment and safety to ensure a supply chain that is uninterrupted for our customers. Flamma continues to constantly look on how internal improvements can bring value to the marketplace such as the building of our cGMP workshop and R&D building in Dalian, China at Flamma Honkai to the new R&D building in Chignolo, Italy that broke ground in 2020. This will enable Flamma to quadruple its R&D space and expand our analytical team. Italy is an attractive destination for foreign-owned pharma companies, with 59% of the Italian pharma industry being formed by these companies. Italy also has a large number of pharma contract manufacturing organization (CMO) facilities. What are according to you the success factors of the Italian producers? The quality of work that Italian CDMOs provide is outstanding. Flamma is proud to help lead this recognition in the industry as more and more companies turn to Flamma to help them with their APIs and other necessary compounds. Italy has been able to establish itself in more severely controller markets such as the American, European and Japanese thanks to its expertise and technology. But what about the obstacles that Italy needs to face, such as bureaucracy? How can Italy be successful against for example the fast-track USA model? The efforts made such as the FDA accepting AIFA audits is helping reduce the bureaucracy but more work needs to be done to help all parties succeed. A partnership and understanding of the demands of new drug development will help all Italian CDMOs succeed. This is good for not only the local economy but also good for the entire global marketplace that expects new and exciting drugs to come forth. Italy is instrumental in this today and will hopefully be even more instrumental in the future. What are your company’s target markets? Can you please describe these markets in terms of their market size, segments and trends? Flamma looks to help pharma companies and biotech companies that have small molecules that they are developing. These companies range from small and virtual to mid-size and big pharma. With the addition of Flamma USA, Flamma can now offer support from its sites in Italy, China and the USA providing a fully integrated supply chain and therefore reducing risks substantially. This adds value when working with a privately held, family run company that has a history dating back to 1950. What is your forecast in terms of market demand to the end of the year and beyond? The forecast is challenging to determine as the entire Covid scenario was completely unexpected. With that said, Flamma is seeing basically business as usual from its customer base as they look towards reputable companies that provide fair prices, realistic timelines, reliable service and deliveries that are in spec. The demand forward appears to be steady for the pharma marketplace. Did the Corona virus outbreak affect your supply chains and target markets and if so in what way? Where do you see lasting effects and lessons from the Covid-19 lockdown? Fortunately, Flamma was minimally affected by Covid. Having a facility in China allowed us to implement policies in Italy and the USA that kept the workforce safe and productive. Flamma has always had the ability to be proactive and move quickly to deal with situations that were unexpected. Covid is just another example if such a situation that, unfortunately, everyone has had to deal with. The coronavirus pandemic as shown us more than ever that we need a crisis-resistant system and the means to produce medicines within the EU to ensure timely access to essential medicines for citizens and hospitals in all circumstances. What do you think could be the strategies for Europe and Italy to guarantee economic accessibility, sustainability and security of supply? Clearly there is no simple answer here. There are reasons for safety stocks of drugs along with multiple suppliers to provide a secure supply chain. The talk of a centralized manufacturing for drugs sounds like a fine idea but the reality is that the marketplace is global and you need to have CDMOs that you can rely on and can react accordingly. Flamma was very quick to provide needed materials for partners who called and, thanks to the hard work of our teams, we were able to mobilize both Italy GIAN PAOLO NEGRISOLI President and CEO, Flamma 76 Chimica Oggi - Chemistry Today - vol. 38(5) September/October 2020 GIAN PAOLO NEGRISOLI President and CEO, Flamma

RkJQdWJsaXNoZXIy MTY5Njg=